BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27567629)

  • 1. The evaluation of sleep quality and response to anti-tumor necrosis factor α therapy in rheumatoid arthritis patients.
    Karatas G; Bal A; Yuceege M; Yalcin E; Firat H; Dulgeroglu D; Karataş F; Sahin S; Cakci A; Ardic S
    Clin Rheumatol; 2017 Jan; 36(1):45-50. PubMed ID: 27567629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of sleep quality in patients with ankylosing spondylitis and efficacy of anti-TNF-α therapy on sleep problems: A polisomnographic study.
    Karatas G; Bal A; Yuceege M; Firat H; Gurcay E; Ardic S; Cakci FA
    Int J Rheum Dis; 2018 Jun; 21(6):1263-1269. PubMed ID: 28556500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysis.
    Minnock P; Veale DJ; Bresnihan B; FitzGerald O; McKee G
    Clin Rheumatol; 2015 Nov; 34(11):1857-65. PubMed ID: 26453249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical, autoimmune, and psychiatric parameters correlate with sleep disturbance in patients with systemic sclerosis and rheumatoid arthritis.
    Bagnato GL; Fiorenza A; Cordova F; Roberts WN; Moore C; Greco D; Monaco C; Muscatello MR; Bruno A; Zoccali R; Bagnato G
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):49-55. PubMed ID: 27192425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE).
    Ceccarelli F; Massafra U; Perricone C; Idolazzi L; Giacomelli R; Tirri R; Russo R; Pistone G; Ruscitti P; Parisi S; Sainaghi PP; Cacciapaglia F; Zullo A; Marino V; Migliore A; Valesini G
    Clin Exp Rheumatol; 2017; 35(1):24-32. PubMed ID: 27974105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
    Mancarella L; Bobbio-Pallavicini F; Ceccarelli F; Falappone PC; Ferrante A; Malesci D; Massara A; Nacci F; Secchi ME; Manganelli S; Salaffi F; Bambara ML; Bombardieri S; Cutolo M; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Grassi W; Lapadula G; Cerinic MM; Montecucco C; Trotta F; Triolo G; Valentini G; Valesini G; Ferraccioli GF;
    J Rheumatol; 2007 Aug; 34(8):1670-3. PubMed ID: 17611987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of treatment with etanercept versus methotrexate on sleep quality, fatigue and selected immune parameters in patients with active rheumatoid arthritis.
    Detert J; Dziurla R; Hoff P; Gaber T; Klaus P; Bastian H; Braun T; Schellmann S; Penzel T; Fietze I; Loeschmann PA; Jaehnig P; Straub RH; Burmester GR; Buttgereit F
    Clin Exp Rheumatol; 2016; 34(5):848-856. PubMed ID: 27385076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug outcome survey to evaluate anti-TNF treatment in rheumatoid arthritis: an Italian observational study (the DOSE study).
    Anecchino C; Fanizza C; Marino V; Romero M;
    Clin Exp Rheumatol; 2015; 33(6):779-87. PubMed ID: 26575614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF-α agents.
    Detorakis EE; Magkanas E; Lasithiotaki I; Sidiropoulos P; Boumpas DT; Gourtsoyiannis N; Antoniou K; Raissaki M
    Clin Exp Rheumatol; 2017; 35(1):43-52. PubMed ID: 27908307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
    Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
    Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
    Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E
    Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
    Genevay S; Finckh A; Ciurea A; Chamot AM; Kyburz D; Gabay C;
    Arthritis Rheum; 2007 May; 57(4):679-85. PubMed ID: 17471545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved Sleep Efficiency after Anti-Tumor Necrosis Factor α Therapy in Rheumatoid Arthritis Patients.
    Taylor-Gjevre RM; Gjevre JA; Nair BV; Skomro RP; Lim HJ
    Ther Adv Musculoskelet Dis; 2011 Oct; 3(5):227-33. PubMed ID: 22870481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
    Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
    J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales.
    Wolfe F; Michaud K; Li T
    J Rheumatol; 2006 Oct; 33(10):1942-51. PubMed ID: 16960928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor necrosis factor-alpha therapy and periodontal parameters in patients with rheumatoid arthritis.
    Mayer Y; Balbir-Gurman A; Machtei EE
    J Periodontol; 2009 Sep; 80(9):1414-20. PubMed ID: 19722791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.